PVLA

Business Context and Reporting Period

This summary covers the Form 10-Q filed by Pieris Pharmaceuticals, Inc. (PIRS) for the quarterly period ended September 30, 2024. Pieris is a biopharmaceutical company that has discontinued its proprietary research and development (R&D) activities to focus on capturing potential milestone payments from partnered immuno-oncology assets and executing a strategic merger. On July 23, 2024, Pieris entered into a definitive merger agreement with Palvella Therapeutics, Inc., under which Pieris will acquire Palvella, and the combined entity will operate under the Palvella name. The transaction is expected to close in the fourth quarter of 2024, subject to stockholder approval and other conditions.

Key Financial Metrics

Debt and Liquidity: The company reported no long-term debt. Current liabilities totaled $4.3 million as of September 30, 2024, down from $11.9 million at year-end 2023. Management believes current funds are sufficient to fund operations for at least the next 12 months.

Material Changes vs. Prior Period

• Revenue Collapse: Revenue dropped to zero in Q3 2024 compared to $19.5 million in Q3 2023. This is due to the satisfaction of all performance obligations under previous collaboration agreements (Pfizer, AstraZeneca, Genentech, Servier). The company no longer has active R&D programs generating revenue.
• Expense Reduction: Total operating expenses decreased significantly to $3.1 million in Q3 2024 from $31.3 million in Q3 2023. This reduction is driven by the discontinuation of all R&D activities, workforce reductions, and the elimination of asset impairment charges (which were $14.9 million in Q3 2023).
• Asset Monetization: The company sold all property and equipment held for sale in the first nine months of 2024, recording a gain of $0.2 million. Consequently, the balance sheet no longer lists property and equipment.
• Stock Split: A 1-for-80 reverse stock split was effected on April 22, 2024. All share and per-share data in this filing have been restated retroactively.

Guidance, Outlook, and Risks

• Merger with Palvella: The primary strategic focus is the merger with Palvella Therapeutics. Upon closing, pre-merger Pieris stockholders are expected to own approximately 18% of the combined company, while pre-merger Palvella stockholders will own approximately 82%. The transaction includes a PIPE financing expected to raise approximately $78.9 million.
• Contingent Value Rights (CVRs): Pre-merger Pieris stockholders will receive CVRs entitling them to potential future milestone and royalty payments from legacy assets (e.g., Pfizer and Boston Pharmaceuticals partnerships). Management currently assesses the likelihood of these payments as remote.
• Future Milestones: Pieris retains rights to potential milestones of up to $15.0 million upon first patient dosing in Phase 2 trials and up to $40.0 million upon pivotal trial dosing for partnered assets SGN-BB228 and BOS-342.
• Risks: Key risks include the failure to consummate the merger, the uncertainty of receiving future milestone payments, the potential for Nasdaq delisting if the merger fails, and the need for additional capital if the merger does not close and the company must liquidate or continue operations independently.

Investor Verification Checklist

• Merger Approval: Verify the status of stockholder votes for both Pieris and Palvella, as the merger is contingent on these approvals.
• PIPE Financing: Confirm the closing of the $78.9 million PIPE financing, which is a condition precedent to the merger.
• Cash Runway: Monitor the company's cash burn rate and confirm if the $19.4 million cash balance remains sufficient to fund operations through the merger closing or potential liquidation scenarios.
• Legacy Asset Milestones: Track the clinical progress of SGN-BB228 (Pfizer) and BOS-342 (Boston Pharmaceuticals) to assess the probability of future milestone payments that would benefit CVR holders.
• Series F Preferred Stock: Note the issuance of one share of Series F Preferred Stock to the Chairman, which carries 25 million votes specifically for the authorized share increase proposal required for the merger.